STOCK TITAN

Revance Therapeutics Inc - RVNC STOCK NEWS

Welcome to our dedicated news page for Revance Therapeutics (Ticker: RVNC), a resource for investors and traders seeking the latest updates and insights on Revance Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Revance Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Revance Therapeutics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.72%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.63%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.74%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.06%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.06%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.06%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.87%
Tags
conferences
Revance Therapeutics Inc

Nasdaq:RVNC

RVNC Rankings

RVNC Stock Data

514.83M
70.80M
8.48%
76%
13.47%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Newark

About RVNC

revance therapeutics, inc. is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. the company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented transmts® peptide delivery system to address unmet needs in the $3 billion neurotoxin market. revance's proprietary transmts technology enables delivery of botulinum toxin a through two novel dose formulations, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a more targeted and potentially longer lasting delivery. revance is currently pursuing clinical development for two product candidates, topical rt001 and injectable rt002, in a broad spectrum of aesthetic and therapeutic indications. rt001 is a topical gel, which has the potential to be the first commercially available non-injectable dose form